Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirtobrutinib + rituximab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pirtobrutinib + rituximab is a combination therapy being investigated for the treatment of B-cell malignancies, specifically indolent clinical forms of mantle cell lymphoma (MCL). Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor that remains effective in the presence of C481 mutations, which typically confer resistance to covalent BTK inhibitors. Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on the surface of B-lymphocytes, inducing cell death through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (GELTAMO) is sponsoring a Phase II trial (GELTAMO-PIRTO-1) to evaluate this combination in treatment-naïve patients with indolent MCL.
- Other names
- P-R combinationPirtobrutinib and rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on pirtobrutinib + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirtobrutinib + rituximab.